AUS
NZ
UK
CA
USA
IND
Highlights:
- Shield Therapeutics (LSE:STX) reports robust Q3 revenue, driven by increased demand for Accrufer.
- The company secures additional financing and targets positive cash flow by the end of 2025.
- A potential $10 million equity investment from AOP Health could elevate its stake to a controlling interest.
Shield Therapeutics PLC (LSE:STX) announced strong sales momentum for the third quarter of 2024, alongside a series of strategic financial steps designed to drive the company toward cash flow positivity by late 2025. The specialty drug company reported that its lead iron deficiency drug, Accrufer, achieved $7.2 million in net revenue, spurred by a 20% increase in prescription volumes over the previous quarter and a notable 86% rise compared to the same period in 2023. With total quarterly revenue reaching $8 million, including royalties and milestone payments, Shield’s year-to-date revenue has reached $20 million. This performance keeps the company on track to hit its annual revenue goal of $31.5 million.
As part of its drive for sustainable growth, Shield expanded its working capital financing arrangement with Sallyport Commercial Finance, increasing its facility from $10 million to $15 million. The additional funds will bolster Shield's capital reserves, enabling it to extend its cash runway well into the second quarter of 2025. Additionally, Shield has taken measures to enhance operational efficiency, implementing a 10% reduction in operating expenses as part of its broader cost-management initiative.
In parallel with these efforts, Shield announced a potential $10 million equity investment from AOP Health, its largest shareholder. This funding would deepen AOP Health’s stake in Shield to a controlling interest, contingent upon shareholder consent and regulatory approval. A non-binding term sheet has been signed to initiate this process, marking a strategic step that could enhance Shield’s financial stability and growth prospects.
Shield’s CEO, Anders Lundstrom, expressed confidence in the company’s trajectory, highlighting the continued demand for Accrufer across global markets. “It has been another successful quarter for Shield as we work toward becoming cash flow positive by the end of FY 2025,” he commented. Lundstrom underscored that positive trends in net sales, prescriptions, and net selling prices reflect growing momentum behind Accrufer. With a solid balance sheet and disciplined cost control, Shield appears positioned to make significant strides in the coming quarters.
As Shield enters the final quarter of 2024, its strengthened financial position, coupled with growing demand for Accrufer, positions the company for further expansion and stability. With its sights set on achieving self-sustaining growth, Shield’s management is focused on transitioning the business to a more resilient and financially independent footing by the end of 2025.
